Cargando…

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

SIMPLE SUMMARY: Osimertinib, a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown marked clinical benefit for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. However, resistance to osimertinib inevitably develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	La Monica, Silvia, Fumarola, Claudia, Cretella, Daniele, Bonelli, Mara, Minari, Roberta, Cavazzoni, Andrea, Digiacomo, Graziana, Galetti, Maricla, Volta, Francesco, Mancini, Maicol, Petronini, Pier Giorgio, Tiseo, Marcello, Alfieri, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792603/ https://www.ncbi.nlm.nih.gov/pubmed/33374971 http://dx.doi.org/10.3390/cancers13010006

Ejemplares similares

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
por: Volta, Francesco, et al.
Publicado: (2023)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
por: La Monica, Silvia, et al.
Publicado: (2019)

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
por: Cavazzoni, Andrea, et al.
Publicado: (2020)

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2018)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
por: Bonelli, Mara A., et al.
Publicado: (2017)

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
por: Fumarola, Claudia, et al.
Publicado: (2017)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
por: Alfieri, Roberta R, et al.
Publicado: (2011)

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN
por: Cavazzoni, Andrea, et al.
Publicado: (2017)

A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC
por: Adorni, Maria Pia, et al.
Publicado: (2023)

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
por: Cretella, Daniele, et al.
Publicado: (2019)

YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs
por: Minari, Roberta, et al.
Publicado: (2022)

Hypertonic Stress and Amino Acid Deprivation Both Increase Expression of mRNA for Amino Acid Transport System A
por: Alfieri, Roberta R., et al.
Publicado: (2005)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method
por: Bozzetti, Cecilia, et al.
Publicado: (2015)

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway
por: Alfieri, Roberta, et al.
Publicado: (2017)

It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
por: Garajová, Ingrid, et al.
Publicado: (2022)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
por: Eltayeb, Kamal, et al.
Publicado: (2022)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
por: Mancini, Maicol, et al.
Publicado: (2021)

Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review
por: Folesani, Giuseppina, et al.
Publicado: (2023)

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
por: Del Re, Marzia, et al.
Publicado: (2018)

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
por: Liang, Muh-Lii, et al.
Publicado: (2020)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
por: Gharbi, Severine Isabelle, et al.
Publicado: (2022)

MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report()()
por: Rihawi, Karim, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3g1sibb2s5ujt9qe2ugi3e0da7